NCT01169675View on ClinicalTrials.gov

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Neoplasms
Interventions
DRUG

BIBW 2992 low dose

patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle

DRUG

BIBW 2992 high dose

patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle

DRUG

pemetrexed

given intravenously on day 1 of a 21 day cycle

DRUG

pemetrexed

given intravenously on day 1 of a 21 day cycle

DRUG

BIBW 2992 high dose 6 day

patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle

DRUG

pemetrexed

given intravenously on day 1 of a 21 day cycle

DRUG

pemetrexed

given intravenously on day 1 of a 21 day cycle

DRUG

pemetrexed

given intravenously on day 1 of a 21 day cycle

DRUG

pemetrexed

given intravenously on day 1 of a 21 day cycle

DRUG

BIBW 2992 low dose 6 day

patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle

DRUG

BIBW 2992 medium dose 6 day

patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle

DRUG

BIBW 2992 medium dose

patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle

Trial Locations (2)

Unknown

1200.92.1001 Boehringer Ingelheim Investigational Site, Edmonton

1200.92.1002 Boehringer Ingelheim Investigational Site, Hamilton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY